Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558386 · ClinicalTrials.gov registry record
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
A clinical trial of Myelodysplastic Syndromes and Hematopoietic Cell Transplant, sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- 92
- Enrollment target
- 6
- Study locations
NCT03558386 is a study of Myelodysplastic Syndromes and Hematopoietic Cell Transplant that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 92 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (68% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT03558386, a study of Myelodysplastic Syndromes and Hematopoietic Cell Transplant, has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- 92 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).
Conditions Studied
Interventions
- BEHAVIORAL ePRO survey
Study Locations (6)
California
- Stanford University - Stanford
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- The Ohio State University - Columbus
Wisconsin
- Froedtert Memorial Lutheran Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2019-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03558386
The ClinicalTrials.gov registry entry for NCT03558386 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (68% lower). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which ePRO survey is the first listed.
NCT03558386 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT03558386 about?
NCT03558386 is a clinical study titled "Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes". This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).
What is the current status of trial NCT03558386?
This trial is currently completed. The enrollment target is 92 participants. The study started on 2018-07-23. Estimated completion is 2019-11-15.
What conditions does trial NCT03558386 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Hematopoietic Cell Transplant.
What interventions are being tested in trial NCT03558386?
The interventions under investigation include: ePRO survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT03558386?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03558386 being conducted?
This trial has 6 study locations across California, Florida, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.